An interventional study of Aspirin and Resolute Integrity DES in Stable Angina, sponsored by CeloNova BioSciences, Inc.. Terminated at 2 sites in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-06.
Sponsored by CeloNova BioSciences, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase one of this study is a prospective, randomized (2:1), pilot study that will evaluate COBRA PzF vascular healing patterns and thrombus formation with Optical Coherence Tomography (OCT) at 3 months after stent implantation in comparison with Resolute Integrity drug eluting stent (DES). Patients in the COBRA PzF (Group 1) will receive dual anti platelets for one week followed by aspirin, while patients implanted with ZES (Group 2), will receive Dual anti-platelet therapy (DAPT) for at least 6 months followed by aspirin.
After the completion of Phase 1, Phase 2 will enroll 10 patients in the COBRA PzF (Group 3). Patients in Group 3 will receive aspirin alone and have OCT at one month after the stent procedure to evaluate COBRA PzF vascular healing patterns and thrombus formation at one month follow up.
Phase one of this study is a prospective, randomized (2:1), pilot study that will evaluate COBRA PzF vascular healing patterns and thrombus formation with Optical Coherence Tomography (OCT) at 3 months after stent implantation in comparison with Resolute Integrity drug eluting stent (DES). Patients in the COBRA PzF (Group 1) will receive dual anti platelets for one week followed by aspirin, while patients implanted with ZES (Group 2), will receive Dual anti-platelet therapy (DAPT) for at least 6 months followed by aspirin.
After the completion of Phase 1, Phase 2 will enroll 10 patients in the COBRA PzF (Group 3). Patients in Group 3 will receive aspirin alone and have OCT at one month after the stent procedure to evaluate COBRA PzF vascular healing patterns and thrombus formation at one month follow up.
This study was terminated after enrollment of 8 patients due to insufficient enrollment
344 studies on the registry are indexed under Angina, Stable; 57 are open to participants now.
This study's enrollment of 8 is below the median of 150 across 231 interventional studies indexed under Angina, Stable.
Browse Angina, Stable studies →CeloNova BioSciences, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COBRA PzF coronary stent followed by dual anti-platelet therapy (DAPT) for one week
Device: COBRA PzF · Drug: DAPT
Resolute Integrity DES followed by dual anti-platelet therapy (DAPT) for at least 6 months
Device: Resolute Integrity DES · Drug: DAPT
COBRA PzF coronary stent followed by aspirin alone
Drug: Aspirin · Device: COBRA PzF
75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
Also known as: Ascriptin Enteric, Aspir 81, Aspir-Low, Bufferin, Easprin, Ecotrin, Ecpirin, Fasprin, Halfprin, Miniprin
Resolute Integrity DES
Also known as: COBRA PzF coronary stent system
At the discretion of the investigator as to which DAPT is administered (per local practice)
Also known as: Dual Anti Platelet Therapy
Neointimal coverage of the stent as measured using OCT
Neointimal coverage of the stent as measured using OCT
Time frame: 1 month
Neointimal coverage of the stent as measured using OCT
Neointimal coverage of the stent as measured using OCT
Time frame: 3 months
Presence of thrombus formation as measured by OCT
Presence of thrombus formation as measured by OCT
Time frame: 1 month
Presence of thrombus formation as measured by OCT
Presence of thrombus formation as measured by OCT
Time frame: 3 months
Proportion of uncovered struts as measured by OCT
Proportion of uncovered struts as measured by OCT
Time frame: 1 month
Proportion of uncovered struts as measured by OCT
Proportion of uncovered struts as measured by OCT
Time frame: 3 months
Presence of Malopposed struts as measured by OCT
Presence of Malopposed struts as measured by OCT
Time frame: 1 month
Presence of Malopposed struts as measured by OCT
Presence of Malopposed struts as measured by OCT
Time frame: 3 months
In-stent neointimal thickness measured using OCT
In-stent neointimal thickness measured using OCT
Time frame: 1 month
In-stent neointimal thickness measured by OCT
In-stent neointimal thickness measured by OCT
Time frame: 3 months
Lumen area measured by OCT
Lumen area measured by OCT
Time frame: 1 month
Lumen area measured by OCT
Lumen area measured by OCT
Time frame: 3 months
Lumen Volume measured by OCT
Lumen Volume measured by OCT
Time frame: 1 month
Lumen Volume measured by OCT
Lumen Volume measured by OCT
Time frame: 3 months
Stent area measured by OCT
Stent area measured by OCT
Time frame: 1 month
Stent area measured by OCT
Stent area measured by OCT
Time frame: 3 months
Stent volume measured by OCT
Stent volume measured by OCT
Time frame: 1 month
Stent volume measured by OCT
Stent volume measured by OCT
Time frame: 3 months
In-stent late loss measured by angiography
In-stent late loss measured by angiography
Time frame: 1 month
In-stent late loss measured by angiography
In-stent late loss measured by angiography
Time frame: 3 months
In-segment late loss measured by angiography
In-segment late loss measured by angiography
Time frame: 1 month
In-segment late loss measured by angiography
In-segment late loss measured by angiography
Time frame: 3 months
In-stent percent diameter stenosis measured by angiography
In-stent percent diameter stenosis (%DS) measured by angiography
Time frame: 1 month
In-stent percent diameter stenosis measured by angiography
In-stent percent diameter stenosis (%DS) measured by angiography
Time frame: 3 months
In-segment percent diameter stenosis measured by angiography
In-segment percent diameter stenosis measured by angiography (%DS) (within the 5 mm margins proximal and distal to stent)
Time frame: 1 month
In-segment percent diameter stenosis measured by angiography
In-segment percent diameter stenosis measured by angiography (%DS) (within the 5 mm margins proximal and distal to stent)
Time frame: 3 months
In-stent binary stenosis measured by angiography
In-stent binary stenosis measured by angiography
Time frame: 1 month
In-stent binary stenosis measured by angiography
In-stent binary stenosis measured by angiography(stenosis of \> 50% of the reference vessel diameter)
Time frame: 3 months
In-segment binary stenosis measured by angiography
In-segment binary stenosis measured by angiography (stenosis of \> 50% of the reference vessel diameter)
Time frame: 1 month
In-segment binary stenosis measured by angiography
In-segment binary stenosis measured by angiography (stenosis of \> 50% of the reference vessel diameter)
Time frame: 3 months
In-stent minimum lumen diameter measured by angiography
In-stent minimum lumen diameter (MLD) measured by angiography
Time frame: 1 month
n-stent minimum lumen diameter measured by angiography
In-stent minimum lumen diameter (MLD) measured by angiography
Time frame: 3 months
In-segment minimum lumen diameter (MLD) measured by angiography
In-segment MLD measured by angiography
Time frame: 1 month
In-segment minimum lumen diameter (MLD) measured by angiography
In-segment MLD measured by angiography
Time frame: 3 months
Longitudinal stent deformation measured by angiography
Longitudinal stent deformation measured by angiography
Time frame: 1 month
Longitudinal stent deformation measured by angiography
Longitudinal stent deformation measured by angiography
Time frame: 3 months
Presence of stent fracture measured by angiography
Presence of stent fracture measured by angiography
Time frame: 1 month
Presence of stent fracture measured by angiography
Presence of stent fracture measured by angiography
Time frame: 3 months
All Deaths
All Deaths from any cause post index procedure
Time frame: 1 month
All Deaths
All Deaths from any cause post index procedure
Time frame: 6 months
All Deaths
All Deaths from any cause post index procedure
Time frame: 12 months
Cardiac Death
Death due to cardiac cause post index procedure
Time frame: 1 month
Cardiac Death
Death due to cardiac cause post index procedure
Time frame: 6 months
Cardiac Death
Death due to cardiac cause post index procedure
Time frame: 12 months
Major Adverse Cardiac Events
Major Adverse Cardiac Events (MACE) defined as cardiac death, MI (Q wave and non-Q wave), emergent bypass surgery, or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods
Time frame: 1 month
Major Adverse Cardiac Events
Major Adverse Cardiac Events (MACE) defined as cardiac death, MI (Q wave and non-Q wave), emergent bypass surgery, or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods
Time frame: 6 months
Major Adverse Cardiac Events
Major Adverse Cardiac Events (MACE) defined as cardiac death, MI (Q wave and non-Q wave), emergent bypass surgery, or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods
Time frame: 12 months
Myocardial Infarction
Occurrence of myocardial infarction. Defined as either a Q wave MI (QWMI) or Non-Q wave MI (NQWMI).
Time frame: 1 month
Myocardial Infarction
Occurrence of myocardial infarction. Defined as either a Q wave MI (QWMI) or Non-Q wave MI (NQWMI).
Time frame: 6 months
Myocardial Infarction
Occurrence of myocardial infarction. Defined as either a Q wave MI (QWMI) or Non-Q wave MI (NQWMI).
Time frame: 12 months
Composite endpoint of cardiac death and MI
Composite endpoint of Cardiac Death and MI
Time frame: 1 month
Composite endpoint of cardiac death and MI
Composite endpoint of Cardiac Death and MI
Time frame: 6 months
Composite endpoint of cardiac death and MI
Composite endpoint of Cardiac Death and MI
Time frame: 12 months
Clinically driven Target Lesion Revascularization
Clinically driven TLR. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.
Time frame: 1 month
Clinically driven Target Lesion Revascularization
Clinically driven TLR. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.
Time frame: 6 months
Clinically driven Target Lesion Revascularization
Clinically driven TLR. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.
Time frame: 12 months
Clinically driven target vessel revascularization
Clinically driven TVR. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion, which includes upstream and downstream branches and the target lesion itself.
Time frame: 1 month
Clinically driven target vessel revascularization
Clinically driven TVR. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion, which includes upstream and downstream branches and the target lesion itself.
Time frame: 6 months
Clinically driven target vessel revascularization
Clinically driven TVR. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion, which includes upstream and downstream branches and the target lesion itself.
Time frame: 12 months
Occurrence of Stroke post index procedure
Stroke (ischemic and hemorrhagic)
Time frame: 1 month
Occurrence of Stroke post index procedure
Stroke (ischemic and hemorrhagic)
Time frame: 6 months
Occurrence of Stroke post index procedure
Stroke (ischemic and hemorrhagic)
Time frame: 12 months
Acute success
Device Success: Defined as the attainment of \< 30% final residual stenosis of the target lesion using only the COBRA PzFTM Coronary Stent System Lesion Success: Defined as the attainment of \< 30% final residual stenosis of the target lesion using any percutaneous method. Procedure Success: Attainment of \< 30% residual stenosis of the target lesion and no in-hospital MACE.
Time frame: 30 days
Bleeding or vascular complications
Bleeding Complications: Defined as a procedure-related hemorrhagic event that requires a transfusion and/or surgical intervention. Vascular Complications may include pseudoaneurysm, arteriovenous fistula (AVF), peripheral ischemia/nerve injury, and vascular event requiring transfusion or surgical repair.
Time frame: At time of hospital discharge (expected average to be within 2 days of index procedure
Stent Thrombosis
Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the patient has left the catheterization laboratory.
Time frame: 3 months
The record gives a start of Jun 2014, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin
CeloNova BioSciences, Inc.